The role of DNA and RNA-containing viruses in the genesis of cancer pathology has been established. Existing cancer prevention studies has shown that vaccinations administered to certain virus carriers (HPV and HBV vaccinations) significantly reduced the incidence of cancer. Antiviral therapy in patients with chronic viral hepatitis B and C has improved the outcomes of primary hepatocellular carcinoma and is recommended in guidelines. However, we found no data on the use of information-based diagnostic methods for SARS-CoV-2, a possible link between this virus and the development of rectal cancer in carriers, or on the results of treatment using information-based methods in this group of patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the COVID-19 pandemic, according to some data, can persist in the human body for an extended period. Recent studies suggest that standard pathogenic mechanisms are present for both SARS-CoV-2 and oncogenesis. SARS-CoV-2 exploits host immunity, stimulates signaling and oncogenic pathways, and may establish an oncogenic microenvironment. Therapy for tumor processes includes chemotherapy, radiation therapy, surgical treatment, immunotherapy, and others. However, to date, no attempts have been made to influence the virus as a risk factor and as a factor contributing to the further spread of the process in patients with already established oncological pathology.

The aim of the research.

To carry out a clinical trial to determine the capabilities of information methods in the diagnosis of SARS-CoV-2 followed by the treatment of patients with rectal cancer before administering traditional methods of therapy to the patient, as per the protocol for managing this group of patients, for the purpose of eliminating the SARS-CoV -2 virus, while the diagnosis of the infectious agent is based on measuring the electrical conductivity at specific acupuncture points located on the surface of the human body (non-invasive approach), and the therapy of the viral infection is carried out using” a device for transferring the information from the drug to a human body”.

What is planned?

For patients with a confirmed diagnosis of stage II-III rectal cancer, medicament testing is planned using nosode of RNA polymerase in C30 dilution, Ribavirin (200 mg, tablets), and Dexamethasone (0.5 mg, tablets) at specially selected acupuncture points. Medicament testing is performed using an electropuncture diagnostic device. Acupuncture points are chosen based on the primary location of the disease, possible metastatic pathways, and the involvement of lymphatic ducts and nodes in the oncological process. Then, patients with a registered positive response to the mentioned drugs undergo exposure using a "device for transferring information from the drug to the human body", into which Ribavirin (200 mg) is placed. The device itself is sequentially positioned over the projection of the patient's organs associated with the acupuncture points at which a positive response to the tested drugs was obtained during medicament testing. 

What is the expected outcome?

Elimination of the virus involved in the oncological process may influence the overall oncological process, including the course of metastatic disease, and may also prevent future cancer recurrence.
We believe there is a link between oncoviruses that cause cancer and the subsequent course of the disease. We hypothesize that eradication of the oncovirus may somehow influence the following course of the oncological process in patients with having rectal cancer.

References